tbuckley/cabot-search huggingface dataset:
Epigenetic Regulation of <i>NAMPT</i> by <i>NAMPT-AS</i>Drives Metastatic Progression in Triple-Negative Breast Cancer
Authors: Hanwen Zhang, Ning Zhang, Ying Liu, Peng Su, Yiran Liang, Yaming Li, Xiaolong Wang, Tong Chen, Xiaojin Song, Yuting Sang, Yi Duan, Jiashu Zhang, Lijuan Wang, Bing Chen, Wenjing Zhao, Haiyang Guo, Zhaojian Liu, Guohong Hu, Qifeng Yang
Journal: Cancer Research (2019)

Abstract Triple-negative breast cancer (TNBC) is highly heterogeneous and has a poor prognosis. It is therefore important to identify the underlying molecular mechanisms in order to develop novel therapeutic strategies. Although emerging research has revealed long noncoding RNAs (lncRNA) as vital to carcinogenesis and cancer progression, their functional involvement in TNBC has not been well defined. In this study, we utilized the The Cancer Genome Atlas (TCGA) database and analyzed clinical samples to show that the long noncoding antisense transcript of nicotinamide phosphoribosyltransferase (NAMPT), NAMPT-AS, is upregulated in TNBC and is associated with poor prognosis, lymph node involvement, metastasis, and advanced stage. NAMPT-AS was cotranscribed with NAMPT from a bidirectional promoter, where the distributions of H3K4me3 and H3K27Ac chromatin modifications were enriched based on ENCODE and FANTOM5, suggesting the potential enhancer-RNA characteristics of NAMPT-AS. NAMPT-AS epigenetically regulated the expression of NAMPT in two divergent ways: NAMPT-AS recruited POU2F2 to activate the transcription of NAMPT, and NAMPT-AS acted as a competing endogenous RNA to rescue NAMPT degradation from miR-548b-3p. NAMPT-AS/NAMPT promoted tumor progression and regulated autophagy through the mTOR pathway in vitro and in vivo. In a cohort of 480 breast cancer patients, NAMPT was associated with breast cancer–specific survival and overall survival. These results demonstrate that NAMPT-AS is an oncogenic lncRNA in TNBC that epigenetically activates NAMPT to promote tumor progression and metastasis. Furthermore, these data identify NAMPT-AS/NAMPT as promising therapeutic targets in patients with TNBC. Significance: Upregulation of the long noncoding antisense RNA of NAMPT gene (NAMPT-AS) is associated with metastasis and poor prognosis in TNBC.
A New Neuroleptic Seeks Its Place
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Form of Record for Hospital Social Work, Including Suggestions on Organization.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer survivorship care in rural community: Provider perspective.
Authors: Katia Noyes, David Holub, Irfan Rizvi, Alex Swanger, Coty Reisdorf, Kenneth Tomaszewski, Louis S. Constine
Journal: Journal of Clinical Oncology (2017)

50 Background: Advances in oncologic sciences have resulted in successful treatments for many cancers with improved survival for millions of patients. Efficient delivery of cancer care now requires not only skills and professionalism of each provider but also well-orchestrated performances of multiple oncology, primary care and social services providers acting as one multidisciplinary team. It is unknown, however, whether providers are prepared for and accept their new roles in patient cancer care teams across region. This study assessed perspectives of providers involved in care for patients with cancer about their changing roles. Methods: We conducted a focus group with a diverse group of stakeholders involved in cancer care (2 primary care physicians, 1 rural surgeon, 2 rural oncologists, 2 oncology nurses, 2 cancer patients and a caregiver). The focus group was conducted using ThinkTank software, a collaborative tool that allows participants to communicate virtually in real time, screen share, express preferences and confidentially rank each other responses. We also conducted two traditional focus groups with rural care managers, nurses, social workers and public health providers. Results: The focus groups identified significant differences in attitudes and beliefs toward regional team-based cancer care between various providers. PCPs ranked oncology issues as less important to their practices compared to other chronic conditions associated with performance metrics and financial incentives. APPs ranked care coordination issues as more important compared to PCP rankings from the same practices. Rural providers identified limited staffing, outdated health IT systems, and lack of expertise as major barriers to multidisciplinary team care. Both patients and providers highlighted importance of trust and face-to-face communication in treatment adherence and choice of care setting. Conclusions: Current health information systems, performance metrics and payment models represent significant barriers to integrated care delivery in oncology and survivorship. Successful implementation of efficient and sustainable regional oncology program will require a multi-dimensional intervention to address each of these barriers.
512P VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
Authors: J.Y. Moon, S-W. Baek, H. Ryu, Y.S. Choi, I-C. Song, H-J. Yun, D-Y. Jo, S. Kim, H.J. Lee
Journal: Annals of Oncology (2016)
Carrier status in hepatitis B: a modern scourge with hope
Authors: F. L. Iber
Journal: JAMA (1982)

Viral hepatitis, type B (HBV) is characterized in the acute phase by the appearance of the hepatitis B surface antigen (HBsAg) marker in the serum. Approximately 7% of clinically diagnosed HBV cases continue to demonstrate HBsAg in the serum for months after the clinical symptoms have disappeared. These patients are identified as "carriers" of hepatitis B. The prevalence of HBsAg carriers in the general population of the United States is estimated to be 0.2% to 0.5%. The majority of these patients are entirely asymptomatic, yet the carrier at times represents a clear health hazard to his contacts. In addition, it is now clear that the HBsAg carrier is at clear risk of liver disease and hepatocellular cancer. There is general agreement at the time of this printing that there is no established way to treat or remove the carrier status in all affected persons. The HBsAg carrier is an important
Evaluation of a new antibacterial agent. Doxycycline monohydrate and doxycycline hyclate (Vibramycin)
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Esophageal Carcinoma Metastatic to the Patella
Authors: Milton E. Ashby
Journal: JAMA (1976)

ANY type of patellar neoplasm, whether benign or malignant, or primary or secondary, is rare. Only 15 cases can be found in the literature, involving metastatic diseases to the patella. Primary sites in these cases were the breast, prostate, lung, lymphatic system, uterine cervix, melanin-forming cells, and esophagus.<sup>1-6</sup> The following case represents only the second report, to our knowledge, of metastatic esophageal carcinoma to the patella in the literature. <h3>Report of a Case</h3> A 55-year-old man was admitted to the hospital in September 1974, with a fourmonth history of progressive dysphagia and weight loss. A barium-swallow examination and esophagoscopy showed a 10-cm esophageal mass, which proved to be epidermoid carcinoma on biopsy. In October 1974, the patient had an esophagectomy and esophagogastrostomy. He received radiation therapy postoperatively and was discharged to outpatient follow-up in November 1974 in good condition. In April 1975, the patient visited the emergency room of
Position statement on training needs in addiction psychiatry
Journal: American Journal of Psychiatry (1996)

Psychiatry has only recently developed training in the area of substance-related disorders. Nevertheless, these illnesses are highly prevalent and are associated with substantial morbidity and mortality. Patients with these disorders often do not encounter or have access to effective treatment. Because of this, the American Psychiatric Association recommends developing improved training to assure that 1) the basic psychiatric residency addresses essential aspects of addiction prevention and treatment, 2) addiction psychiatry fellowships are strengthened to provide needed manpower for consultation, academic teaching, and research, and 3) psychiatrists are trained to provide leadership for the multidisciplinary teams characteristic of this field. This statement was drafted by the Committee on Training and Education in Addiction Psychiatry. It was approved by the APA Assembly in November 1995 and by the Board of Trustees in December 1995.
Random Selection
Authors: S. Raymond Gambino
Journal: JAMA (1963)

<h3>To the Editor:</h3> —The letters of Dr. Iversen and associates and of Dr. Friedberg (<i>JAMA</i><b>183</b>:903 [March 9] 1963) show a misunderstanding of the term, "random selection." Alternate selection of cases, of days, or of wards is not random selection. Alternate selection of hospitals is not random selection. Dr. Donald Mainland, Professor of Medical Statistics at New York University College of Medicine, in his<i>Notes From a Laboratory of Medical Statistics # 3</i>has this to say: By a strictly automatic random process we mean the kind of process that is used in games of chance.... Since random has the colloquial meaning of haphazard, the only safe way to distinguish the technical use of the word is by a phrase such as "strictly random", or by naming the process (e.g., the use of random numbers).... Spend a week or two shuffling cards or mixing disks, and see, as others have
Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma.
Authors: D. Ilson, Y. Y. Janjigian, M. A. Shah, D. P. Kelsen, L. H. Tang, J. Campbell, L. Fuqua, M. Capanu
Journal: Journal of Clinical Oncology (2011)

4100 Background: Sorafenib is a tyrosine kinase inhibitor targeting VEGFr, PDGFr, Raf and other pathways. Encouraging response and survival were observed in a phase II trial combining sorafenib with chemotherapy in GE cancer (J Clin Oncol 27:2947;2010). We are studying single agent sorafenib in a phase II trial with the primary endpoint to assess progression-free survival (PFS). Secondary endpoints include response and therapy tolerance. Methods: Patients (pts) with measurable metastatic E and GEJ cancer with no more than 3 prior chemotherapy regimens were treated with sorafenib 400 mg BID. CT scans were performed monthly for the first 2 months, then every 2 months. Results: Twenty of 35 pts have been accrued and 16 are currently evaluable, 17 male, 3 female, median KPS 80%, age 59, GEJ 6, E 14, squamous 2, adenocarcinoma (AC) 18. An ongoing complete response (15+ months) was observed in a pt with biopsy proven metastatic neck lymphadenopathy (E primary AC, recurrence after prior chemoradiotherapy and surgery). A second pt (GEJ AC) had protracted stable disease in bulky celiac node disease (19+ months). Grade 3 toxicity was limited to skin rash (1 pt), hand foot reaction (2 pt), and fatigue (1 pt). Only 4 of 16 pts (25%) had early disease progression at 2 months or less. Median PFS 3.7 mos, 4 patients (25%) received drug for more than 7 months. The majority of tumors tested positive for phospho-erk by immunohistochemistry (14/17, 75%). Conclusions: The observation of a durable complete response and protracted stable disease to sorafenib in E cancer is remarkable. Further accrual continues to define PFS. Supported by a grant from Bayer.
MEDICAL ECONOMICS
Authors: M. L. HARRIS
Journal: JAMA (1927)

It is a trite aphorism that doctors are poor business men, by which is meant that the average doctor knows nothing about the underlying principles of good business; that he is unacquainted with the laws of economics, and that as a rule he is the most gullible of all men when it comes to investing money. Unfortunately there is too much truth in the statement. Why is it that doctors use so little judgment when it comes to matters of business? It is because they practice a profession that for centuries has dwelt in the shadow of altruistic tradition; because they have been so wrapped up in the scientific aspect of their work that they have neglected to a great extent the material affairs of life; because they have had little or no training in business affairs; because by reason of listening from day to day to the ills and
100 Years of Nature
Authors: J.R. E.
Journal: Annals of Internal Medicine (1970)

Editorial Notes1 January 1970100 Years of NatureJ.R. E.J.R. E.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-72-1-141_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe British weekly Nature is one of the world's leading journals of science. It has always been published by the house of Macmillan, and in it have appeared the reports of many of the important scientific theories and discoveries of the past century. In the issue of November 1, 1969, Nature celebrates its 100th birthday.This centenary issue ofNatureis an unusual one. Reprinted are some of the famous papers of the past that first appeared in the journal: Cockcroft and Walton's report in 1932 of the first artificial disintegration of the atomic nucleus, Meitner and Frisch's account in... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 January 1970Volume 72, Issue 1Page: 141-141 ePublished: 1 December 2008 Issue Published: 1 January 1970 PDF downloadLoading ...
Scandinavian Journal of Clinical &amp;amp; Laboratory Investigation, Oslo
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Coronary Heart Disease Incidence, by Sex
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A comparison of meta-analytic results using literature vs individual patient data. Paternal cell immunization for recurrent miscarriage
Authors: G. T. Jeng
Journal: JAMA (1995)

<h3>Objective.</h3> —To compare the meta-analytic results from published literature vs those obtained from pooling original patient data. <h3>Data Sources.</h3> —Individual patient data from 15 completed or ongoing trials on paternal white blood cell immunization as treatment for recurrent miscarriage were obtained through the American Society for Reproductive Immunology. <h3>Study Selection.</h3> —Only randomized controlled trials were selected. Within these eight selected trials, 202 patients were from four published studies, 43 were added by the same investigators after publication, and 140 were from four unpublished trials. <h3>Data Extraction.</h3> —Individual patient data were collected using a standardized form and double data entry. <h3>Data Synthesis.</h3> —Using the fixed treatment effect model, we found that the effect of immunization, denoted as the relative live-birth ratio (RR), was greater by pooling summary data from published articles (RR, 1.29; 95% confidence interval [CI], 1.03 to 1.60) than by pooling all individual patient data from the same investigators (RR, 1.17; 95% CI, 0.97 to 1.37) or when individual patient data were pooled from four unpublished trials (RR, 1.01; 95% CI, 0.74 to 1.28). A similar diminishing treatment effect for the same comparisons was observed using the random treatment effect model (RR, 1.38; 95% CI, 0.89 to 1.87 using published summary data; RR, 1.18; 95% CI, 0.98 to 1.42 using individual patient data; RR, 1.01; 95% CI, 0.74 to 1.28 using unpublished trials). <h3>Conclusions.</h3> —Meta-analytic results may differ depending on the use of various data sources: whether the source was from summary statistics in the literature, from individual patient data provided by trialists, or from unpublished trials. (<i>JAMA</i>. 1995;274:830-836)
AN ORIGINAL METHOD FOR LANTERN SLIDE PROJECTION OF ROENTGEN-RAY FILMS OF THE MASTOID
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Caring (Really) for Patients Who Use Alternative Therapies for Cancer
Authors: Morie A. Gertz, Brent A. Bauer
Journal: Journal of Clinical Oncology (2001)

Article Tools THE ART OF ONCOLOGY: WHEN THE TUMOR IS NOT THE TARGET Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.23.4346 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11731520 Caring (Really) for Patients Who Use Alternative Therapies for Cancer Morie A. GertzxMorie A. GertzSearch for articles by this author , Brent A. BauerxBrent A. BauerSearch for articles by this author Show More From the Division of Hematology and Internal Medicine and Area General Internal Medicine, Mayo Clinic, Rochester, MN. https://doi.org/10.1200/JCO.2001.19.23.4346 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology